Market capitalization | CAD396.67m |
Enterprise Value | CAD771.48m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.75 |
P/S ratio (TTM) P/S ratio | 1.41 |
P/B ratio (TTM) P/B ratio | 0.74 |
Revenue growth (TTM) Revenue growth | -20.59% |
Revenue (TTM) Revenue | CAD280.50m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Canopy Growth Corporation forecast:
9 Analysts have issued a Canopy Growth Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 281 281 |
21%
21%
|
|
Gross Profit | 62 62 |
407%
407%
|
|
EBITDA | -56 -56 |
80%
80%
|
EBIT (Operating Income) EBIT | -101 -101 |
71%
71%
|
Net Profit | -565 -565 |
57%
57%
|
In millions CAD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Head office | Canada |
CEO | David Klein |
Employees | 1,029 |
Founded | 2009 |
Website | www.canopygrowth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.